Reforzamiento intramiocárdico tardío en pacientes posquimioterapia.

Background: the cardiotoxic effects of antineoplastic treatments have been described for several years. The development of non-invasive cardiovascular imaging, and especially cardiac magnetic resonance, have permitted a better understanding of the physiopathology, and earlier diagnosis of these complications. The objective of this study was to evaluate intramyocardial delayed enhancement in Mexican population which received antineoplastic treatment (cisplatin + vinorelbine ± nimotuzumab) for cervico-uterine cancer. This is the first study to evaluate cardiotoxicity diagnosed by cardiac magnetic resonance in patients who take these drugs. Material and methods: a prolective and prospective observational study in 46 patients with diagnosis of stage 4 cervical carcinoma, between 25 and 70 years of age, treated with first-line chemotherapy, without radiological evidence of metastasis, without prior cardiovascular comorbidity. Subjects underwent cardiac magnetic resonance before receiving chemotherapy and 6 months after. Results: the patients' average age was 49 ± 9.6 years. In the initial study, 34.8% of patients had delayed enhancement with insignificant increase (to 41.3%) in the studio at the end of the follow-up period. No significant changes were observed in hemodynamic parameters of the left ventricle following chemotherapy. Ventricular remodeling was observed in 17.4% and drop in left ventricular ejection fraction (of at least 10 percentage points) in 8.6%. Conclusion: cancer patients present intramyocardial delayed enhancement from before antineoplastic treatment. Following administration of chemotherapy signs of ventricular remodeling can be observed in short-term follow-up. [ABSTRACT FROM AUTHOR]